Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)

被引：0
|
作者：
Kortuem, M. [1 ]
Terpos, E. [2 ]
Badros, A. [3 ]
Popat, R. [4 ]
Rodriguez-Otero, P. [5 ]
Farooq, A. [6 ]
Jeng, B. [3 ]
Esposti, Degli S. [7 ,8 ]
Lewis, E. [9 ]
Gupta, I [10 ]
Opalinska, J. [10 ]
Palumbo, A. [11 ]
Trudel, S. [12 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] Univ Coll London Hosp, NHS Fdn Trust, London, England
[5] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[8] UCL Inst Ophthalmol, London, England
[9] GlaxoSmithKline, Res Triangle Pk, NC USA
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] GlaxoSmithKline, Zug, Switzerland
[12] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep211
引用
收藏
页码：204 / 204
页数：1
相关论文
共 30 条
  • [11] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [12] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [13] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
  • [14] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [15] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [16] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [17] LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Collins, J.
    van Noort, M.
    Rathi, C.
    Post, T.
    Struemper, H.
    Jewell, R.
    Ferron-Brady, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S16 - S17
  • [18] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Baron, January
    Doherty, Allison
    Lewis, Eric
    Opalinska, Joanna
    Paka, Prani
    Piontek, Trisha
    Gupta, Ira
    Farooq, Asim V.
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
  • [19] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
    Trautmann-Grill, K.
    Lonial, S.
    Nooka, A. K.
    Thulasi, P.
    Badros, A. Z.
    Jeng, B. H.
    Callander, N. S.
    Sborov, D.
    Zaugg, B. E.
    Popat, R.
    Degli, Esposti S.
    Baron, J.
    Doherty, A.
    Lewis, E.
    Opalinska, J.
    Paka, P.
    Piontek, T.
    Gupta, I
    Farooq, A., V
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
  • [20] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante-Barrigon, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Greil, Richard
    Melchardt, Thomas
    Antonioli, Elisabetta
    Schjesvold, Fredrik
    Lysen, Anna
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    Mouro, Jorge
    D'Estrube, Tim
    Fry, Mark
    Byrne, Julie
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
123